Febantel

As a core anthelmintic component in the field of broad-spectrum anthelmintics, febantel is a benzimidazole prodrug. After entering the animal body, it can be metabolized and transformed into active metabolites such as fenbendazole and oxfendazole through the liver, irreversibly inhibiting the tubulin polymerization of parasites, blocking their glucose uptake, and further leading to energy depletion and death of the parasites. This drug has a good anthelmintic effect on most gastrointestinal nematodes such as roundworms, hookworms, whipworms, tapeworms and some flukes in livestock and poultry, and also has the effect of killing eggs. It is a commonly used anthelmintic component in livestock and poultry breeding such as pigs, poultry and companion animals, as well as in pet medical scenarios. It can also be combined with praziquantel, ivermectin and other components to form compound preparations to expand the anthelmintic spectrum.

The global market size of veterinary anthelmintics has exceeded 8.5 billion US dollars in 2023, among which benzimidazole drugs account for about 18%. With the characteristics of low toxicity and broad spectrum, febantel has accounted for more than 23% of the market share in the pig anthelmintic segment, and its compound annual market growth rate has remained at 6.2% in the past three years. At present, the global production capacity of febantel API is mainly concentrated in China and India, and Chinese manufacturers account for 62% of the global market share. With the continuous improvement of the scale rate of domestic animal husbandry, the growth rate of domestic market demand for febantel is higher than the global average, reaching 8.7%. Since the patent of this drug has long expired, the market competition is dominated by large-scale generic pharmaceutical enterprises, the price system is relatively stable, and there is no relevant policy impact of centralized procurement for the time being.

The original research enterprise of febantel is Bayer Aktiengesellschaft, and the original research trade name is "Banminth". Its core compound patent expired globally in 1979. The main commercial dosage forms are oral premixes and tablets, and the conventional specifications include 50mg/g premix, 150mg/tablet, 500mg/tablet, etc. The original research preparation has been included in the Reference Listed Drug Catalogue by the FDA. Up to now, there are 12 registration records of febantel API on the API Registration Platform of China Center for Drug Evaluation (CDE), among which 8 are in the status of "A (approved for use in marketed preparations)". A number of domestic enterprises have been approved to produce febantel-related veterinary preparations, and no human-use preparation has been approved for marketing. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO provides a full set of febantel impurity reference standards, covering all categories required for research such as synthetic process impurities and degradation impurities. Most products are in regular stock. Spot orders placed before 16:00 can be shipped on the same day. All products meet the requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and can directly support the API quality research, preparation stability investigation and registration declaration of this variety.